LIFE SAVING DRUGS PROGRAM EXPERT PANEL

16th MEETING: 20 October 2023

**AGENDA**

1. **Standing business**
   1. Welcome, apologies and Conflicts of Interest
   2. Update on actions from previous meetings
   3. Correspondence
   4. Report from the Secretariat
2. **Reviews of existing LSDP medicines**
   1. Process for 24 month reviews
   2. Update on upcoming 24 month reviews
3. **Applications for new LSDP medicines**
   1. Olipudase alfa (Xenpozyme®) – for the treatment of acid sphingomyelinase deficiency (ASMD)types A/B and B
4. **Other business**
   1. Expert Panel input to HTA Policy and Methods Review